Aqemia
Last verified 2026-05-16. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $32.4Mattributed |
|---|---|
| Latest round | series-a, $32.4M, 2024-01-01attributed |
| Founded | 2019 |
| Headquarters | Paris, France |
| Industry | bio |
| Stage | series-a |
| Website | aqemia.com |
AQEMIA advances medicine discovery by combining generative AI with deep physics to develop new drugs. The company serves pharmaceutical researchers and organizations seeking to overcome conventional discovery limitations. Its differentiator is the integration of physics-based AI engines that enable drug development at scale beyond.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-01-01 | series-a | $32.4M | undisclosed |
Detected tech stack
Netlify, Next.js, React, Webpack
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $32.4M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $32.4M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | aqemia.com, read 2026-05-16 |
| Description | self-reported | aqemia.com, read 2026-05-16 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.